OPKO Health, Inc. (NASDAQ:OPK) Share Holdings Reduced by Assenagon Asset Management SA

Assenagon Asset Management SA reduced its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK – Free Report) by 51.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 614,720 shares of the biotechnology company’s stock after selling 639,088 shares during the period. Assenagon Asset Management SA’s holdings in OPKO Health were worth $780,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Hennion & Walsh Asset Management Inc. raised its stake in OPKO Health by 11.4% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 776,020 shares of the biotechnology company’s stock valued at $931,000 after purchasing an additional 79,525 shares during the period. Moseley Investment Management Inc. bought a new position in shares of OPKO Health in the first quarter valued at approximately $41,000. Tidal Investments LLC acquired a new position in shares of OPKO Health in the first quarter valued at about $239,000. Comerica Bank boosted its holdings in OPKO Health by 125.0% in the first quarter. Comerica Bank now owns 90,000 shares of the biotechnology company’s stock worth $108,000 after buying an additional 50,000 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in OPKO Health in the 1st quarter worth about $26,000. 64.63% of shares are currently held by institutional investors.

OPKO Health stock performance

Shares of NASDAQ OPK opened at $1.61 on Friday. The company has a quick ratio of 1.62, a current ratio of 1.91, and a debt-to-equity ratio of 0.27. OPKO Health, Inc. has a 12-month low of $0.85 and a 12-month high of $1.90. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -4.60 and a beta of 1.65. The company has a fifty day simple moving average of $1.39 and a 200 day simple moving average of $1.25.

OPKO Health (NASDAQ:OPK – Get Your Free Report ) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.08. OPKO Health had a negative net margin of 31.44% and a negative return on equity of 17.89%. The company had revenue of $182.20 million during the quarter, compared to analyst estimates of $184.70 million. During the same period in the previous year, the firm earned ($0.03) earnings per share. The company’s quarterly revenue was down 31.3% year over year. Sell-side analysts predict that OPKO Health, Inc. will post -0.37 EPS for the current year.

Changes in Analyst Ratings

A number of analysts have recently commented on OPK shares. Barrington Research increased their price objective on OPKO Health from $1.50 to $2.25 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Piper Sandler cut their price target on shares of OPKO Health from $5.00 to $3.00 and set an “overweight” rating for the company in a report on Thursday, July 18th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, May 8th. Finally, StockNews.com raised shares of OPKO Health to a “sell” rating in a research note on Saturday, July 27th.

See the latest stock analysis on OPK

Insider buying and selling

In related news, majority shareholder Opko Health, Inc. sold 14,082 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $28.23, for a total transaction of $397,534.86. Following the transaction, the insider now directly owns 3,469,521 shares of the company’s stock, valued at $97,944,577.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed via this link. Over the last 90 days, insiders have sold 736,644 shares of company stock valued at $23,874,134. Company insiders own 47.26% of the company’s shares.

OPKO health profile

(Free report)

OPKO Health, Inc, a healthcare company, engages in diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico and internationally. The company’s Diagnostics segment operates BioReference Laboratories which provides laboratory testing services for the detection, diagnosis, evaluation, monitoring and treatment of diseases, including esoteric testing, molecular diagnostics, anatomic pathology, genetics, women’s health and correctional healthcare to medical offices, clinics. , hospitals, employers and government units; and the 4Kscore test for prostate cancer.

Read more

Want to see what other hedge funds own OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for OPKO Health, Inc. (NASDAQ:OPK – Free Report).

Get news and reviews for OPKO Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OPKO Health and related companies with MarketBeat.com ‘s FREE daily email newsletter.